All In Biotech

NDA 011839 · Pfizer

Provera

Medroxyprogesterone Acetate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

Jun 18, 1959

Approved uses

4

Original approval plus efficacy supplements

Registered trials

183

47 Phase 3, 16 recruiting

FAERS reports

28,420

26,121 serious, 818 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia .) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders . ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an...

What it is approved for

From the label in effect Jun 29, 2026.

INDICATIONS AND USAGE PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 4, 1998 Supplement 68 · Efficacy ReviewLetter
  • Jul 23, 1979 Supplement 39 · Efficacy
  • Jun 6, 1979 Supplement 35 · Efficacy
  • Jun 18, 1959 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • PROVERA · MEDROXYPROGESTERONE ACETATE 5MG · TABLET, ORAL · Prescription · TE AB
  • PROVERA · MEDROXYPROGESTERONE ACETATE 2.5MG · TABLET, ORAL · Prescription · TE AB
  • PROVERA · MEDROXYPROGESTERONE ACETATE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Medroxyprogesterone" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer female9,758
  • breast cancer8,138
  • breast cancer metastatic1,380
  • meningioma854
  • oestrogen receptor assay positive773
  • progesterone receptor assay positive673
  • pain521
  • drug ineffective520
  • breast cancer in situ516
  • ovarian cancer499
  • nausea470
  • fatigue448

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,215
20052,334
20061,804
2007811
20081,983
20093,953
20106,981
20111,312
2012567
2013249
2014234
2015296
2016316
2017264
2018299
2019368
2020407
2021320
2022301
2023315
2024445
2025883
2026762

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Aug 31, 2026

    PROVERA, Tablet, 10 mg (NDC 0009-0051-01). Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.

  • To Be Discontinued · updated Aug 31, 2026

    PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01). Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.

  • To Be Discontinued · updated Nov 19, 2026

    Provera, Tablet, 5 mg (NDC 0009-0287-01). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Provera (Medroxyprogesterone Acetate)

2024 spending

$35K

Beneficiaries

56

144 claims

Per beneficiary

$619

$3.47 per unit

View as table
YearSpending
2020$54,369
2021$51,051
2022$43,366
2023$34,225
2024$34,680

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,632 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.